Cancer Research

Opposition Leader Urges Faster Vaccine Production at Dei BioPharma Inspection
Research & Development Opposition Leader Urges Faster Vaccine Production at Dei BioPharma Inspection

Uganda’s Leader of Opposition, Joel Ssenyonyi, alongside a group of 15 other Members of Parliament, recently conducted an insightful inspection of the Dei BioPharma facility located in Matugga. This visit, which took place on September 19, 2024, marked a significant milestone that underscored the f

September 20, 2024
Kaida BioPharma Enhances Social Media Presence to Combat Cancer
Research & Development Kaida BioPharma Enhances Social Media Presence to Combat Cancer

Kaida BioPharma, an emerging pharmaceutical company based in Fort Lauderdale, Florida, has announced the launch of its new corporate social media channels. This significant development aims to enhance the company’s presence across various platforms, including X, LinkedIn, and Facebook. By l

September 19, 2024
FDA Approves Kisqali Expanding Breast Cancer Treatment Options Over Verzenio
Research & Development FDA Approves Kisqali Expanding Breast Cancer Treatment Options Over Verzenio

In a significant move likely to reshape the competitive landscape, the FDA has granted approval for Novartis’ Kisqali, when paired with an aromatase inhibitor, for the adjuvant treatment of HR-positive, HER2-negative stage 2 and 3 breast cancer at high risk of recurrence post-surgery. This approval

September 19, 2024
iTeos’ Belrestotug and Jemperli Combo Shows Promise in Lung Cancer Trial
Research & Development iTeos’ Belrestotug and Jemperli Combo Shows Promise in Lung Cancer Trial

The world of cancer treatment is ever-evolving, and recent developments have brought a glimmer of hope for those battling non-small cell lung cancer (NSCLC). iTeos Therapeutics has unveiled promising results from a mid-stage clinical trial examining the efficacy of combining their drug,

September 16, 2024
Are New Cancer Treatments Bringing Hope to Patients with NSCLC?
Research & Development Are New Cancer Treatments Bringing Hope to Patients with NSCLC?

Recent advancements in cancer treatments have provided new hope for patients, with significant progress showcased in the biopharmaceutical industry. The interim results of ArriVent BioPharma, Inc.'s Phase 1b FURTHER trial for their drug firmonertinib have been particularly promising. This

September 13, 2024
Can Ivonescimab Become the New Standard in NSCLC Treatment?
Research & Development Can Ivonescimab Become the New Standard in NSCLC Treatment?

In a significant advancement for non-small cell lung cancer (NSCLC) treatment, Akeso and Summit Therapeutics have revealed astounding results from their phase 3 HARMONi-2 trial. Ivonescimab, a PD-1/VEGF bispecific antibody, has demonstrated remarkable efficacy against Merck’s Keytruda, positioning i

September 9, 2024
Loading

Subscribe to our weekly news digest!

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for subscribing.
We'll be sending you our best soon.
Something went wrong, please try again later